A phase II study of topotecan administered five times daily in patients with advanced gastric cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 6, 1997, Pages 621-625

  Saltz, Leonard B ^a,b   Schwartz, Gary K ^a   Ilson, David H ^a   Quan, Valerie ^a   Kelsen, David P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Camptothecin; Gastric cancer; Phase II study; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; TOPOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TOPOTECAN;

EID: 0030703255     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199712000-00018     Document Type: Article

References (35)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA 1996;46:5-21.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
3. Macdonald JS, Gohmann JJ. Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 1989; 15(suppl 4):42-9.
4. Wils J, Bleiberg H, Dalesio O, et al. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with Adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986;4:1799-803.
5. Preusser P, Wilke H, Achterrath W, et al. Phase II study with the combination of etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7: 1310-7.
6. ECF). Ann Oncol 1994;5:609-16.
7. Wils JA, Klein HO, Wagener DJT, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer. J Clin Oncol 1991;9:827-31.
8. Webb A, Cunningham D, Scarffe JH, et al. A randomized trial comparing ECF with FAMTX in advanced oesophago-gastric cancer. Proc Am Soc Clin Oncol 1996; 15:465.
9. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents: the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966;88:3888-90.
10. Gottlieb JA. Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium,NSC-100880). Cancer Chem Rep 1970;54:461-70.
11. Moertel CG, Schutt AF, Reitemeier RJ, Hah RG. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chem Rep 1972;56:95-101.
12. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chem Rep 1972;56:515-21.
13. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biochem 1985;260:14.873-8.
14. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.
15. Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988;34:755-60.
16. Hsiang YH, Lihou M, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I: DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49:5077-82.
17. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation of antitumor activity. Cancer Res 1989; 49:1465-9.
18. Johnson RK, McCabe FL, Faucette LF, et al. SK&F 104864, a water soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models. Proc Am Assoc Cancer Res 1989;30:623.
19. Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991;34:98-107.
20. SK&F Clinical Research and Development. Investigator Brochure on SK&F 104864. King of Prussia, PA: Smith Kline Beecham Laboratories, 1988.
21. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH. Effect if P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK-F 104864, a new camptothecin analogue. Cancer Res 1992;52:2269-78.
22. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 1991; 51:3052-5.
23. Saltz L, Sirott M, Young C, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte-colony stimulating factor. J Natl Cancer Inst 1993;85:1499-507.
24. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10:647-56.
25. Kambe M, Wakui A, Nakao I, et al. A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancer [Abstract]. Proc Am Soc Clin Med 1993; 12:a584.
26. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative with metastatic colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1991; 10:a408.
27. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
28. Miller AB, Hoogstraten B, Staquet M, et al. Reporting of results of cancer treatment. Cancer 1981;47:206.
29. Schellens JHM, Ma J, Loos WJ, Kolker HJ, Stoter G. Inhibition of removal of cisplatin-induced interstrand crosslinks by topotecan. Proc Am Assoc Cancer Res 1995;36:441.
30. Kozelsky TK, Bonner JA. Sequence dependent interaction of etoposide and topotecan. Proc Am Assoc Clin Res 1995;36:293.
31. Creemers GJ, Gerrits CHJ, Planting AST, et al. Phase II study of topotecan administered as a 21 day continuous infusion to patients with colorectal cancer. Eur J Cancer 1995;31A(suppl 5):S146.
32. Saltz L, Kemeny N, Soignet S, et al. A phase II study of 9-aminocamptothecin in patients with fluorouracil-refractory colorectal cancer. Proc Am Soc Clin Oncol 1996; 15:204.
33. Carmichael J, Gordon A, Malfetano J, et al. Topotecan, a new active drug vs. paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 1996; 15:283.
34. Ardizzoni A, Hansen HH, Dombernowsky P, et al. Phase II study of topotecan in refractory and sensitive small cell lung cancer. Eur J Cancer 1995;31 A(suppl 5):S19.
35. Houghton PJ, Cheshire PJ, Meyers L, Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxy-camptothecin (topotecan) against xenografts derived from adult and childhood tumors [Abstract]. In: Proceedings of the NCI-EORTC Symposium 1992;7:a104.